Page last updated: 2024-11-08

betamethasone acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID443967
CHEMBL ID1200538
CHEBI ID31275
SCHEMBL ID7592
MeSH IDM0582748

Synonyms (62)

Synonym
unii-ti05ao53l7
nsc 759196
betamethasone acetate [usp:jan]
ti05ao53l7 ,
pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11beta,16beta)-
beta-methasone acetate
(11beta,16beta)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate
betamethasone acetate
9-fluoro-11beta,17-dihydroxy-16beta-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate
CHEBI:31275 ,
987-24-6
betamethasone acetate (jan/usp)
D01402
9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 21-acetate
pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(acetyloxy)-, (11beta,16beta)-
einecs 213-578-6
B3165
9alpha-fluoro-11beta,17alpha,21-trihydroxy-16beta-methyl-1,4-pregnadiene-3,20-dione 21-acetate
betamethasone 21-acetate
nsc-759196
CHEMBL1200538
AKOS015896575
(11b,16a)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 21-acetate
betamethasone acetate [ep monograph]
osurnia component betamethasone acetate
betamethasone acetate [ep impurity]
dexamethasone acetate impurity d [ep impurity]
betamethasone acetate [green book]
celestone soluspan component betamethasone acetate
betamethasone acetate [who-dd]
betamethasone acetate [usp monograph]
betamethasone acetate component of osurnia
pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-(acetyloxy)-, (11.beta.,16.beta.)-
betamethasone acetate [usp-rs]
betamethasone acetate [orange book]
betamethasone acetate component of celestone soluspan
betamethasone acetate [mart.]
betamethasone acetate [jan]
betamethasone acetate [vandf]
SCHEMBL7592
betamethason-21-acetat
AKUJBENLRBOFTD-QZIXMDIESA-N
DTXSID8022668 ,
betamethasone acetate, european pharmacopoeia (ep) reference standard
betamethasone acetate, united states pharmacopeia (usp) reference standard
betamethasone acetate, pharmaceutical secondary standard; certified reference material
betamethasone 21
betamethasone-21-acetate
Q27114254
betamethasone (acetate)
betamethasone-acetate
AMY39051
T71509
betamethasone21-acetate
betamethasone acetate (ep impurity)
betamethasone acetate (ep monograph)
betamethasone acetate (mart.)
dtxcid402668
betamethasone acetate (usp monograph)
dexamethasone acetate impurity d (ep impurity)
betamethasone acetate (usp-rs)
9alpha-fluoro-16beta-methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-acetate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Compound-Compound Interactions

ExcerptReferenceRelevance
" Building on earlier findings, we hypothesized that when administered in combination with slow-release betamethasone acetate, betamethasone phosphate and the high maternal-fetal betamethasone concentrations it generates are redundant for fetal lung maturation."( Betamethasone phosphate reduces the efficacy of antenatal steroid therapy and is associated with lower birthweights when administered to pregnant sheep in combination with betamethasone acetate.
Carter, S; Fee, EL; Furfaro, L; Jobe, AH; Kemp, MW; Newnham, JP; Saito, M; Schmidt, AF; Takahashi, T; Takahashi, Y; Usuda, H; Yaegashi, N, 2022
)
1.13

Dosage Studied

Low-dosage treatment with betamethasone acetate was tested against a standard dosage. The dosage was recommended by the American College of Obstetricians and Gynecologists.

ExcerptRelevanceReference
"Antenatal steroids are standard of care for women who are at risk of preterm delivery; however, antenatal steroid dosing and formulation have not been evaluated adequately."( Low-dose betamethasone-acetate for fetal lung maturation in preterm sheep.
Furfaro, L; Jobe, AH; Kallapur, SG; Kannan, PS; Kemp, MW; Kramer, BW; Newnham, JP; Rittenschober-Böhm, J; Saito, M; Schmidt, AF; Stock, S; Usuda, H; Watanabe, S, 2018
)
0.48
" Antenatal corticosteroid dosing remains nonoptimized, and there is little understanding of how different treatment-to-delivery intervals may affect treatment efficacy."( The duration of fetal antenatal steroid exposure determines the durability of preterm ovine lung maturation.
Bridges, J; Eddershaw, PJ; Fee, EL; Furfaro, L; Hanita, T; Jobe, AH; Kemp, MW; Kumagai, Y; Musk, GC; Newnham, JP; Payne, MS; Saito, M; Sato, S; Schmidt, AF; Smallwood, K; Stinson, L; Takahashi, T; Usuda, H; Watanabe, S, 2020
)
0.56
" Trying to take into account both efficacy and safety, we simulated different dosing schemes in order to maintain a maximum of fetuses above 1 ng/mL without exceeding the total standard dose."( Maternal Betamethasone for Prevention of Respiratory Distress Syndrome in Neonates: Population Pharmacokinetic and Pharmacodynamic Approach.
Benaboud, S; Bouazza, N; Foissac, F; Goffinet, F; Hirt, D; Jarreau, PH; Kayem, G; Lui, G; Mandelbrot, L; Rozenberg, P; Tréluyer, JM; Ville, Y; Zheng, Y, 2020
)
0.56
" However, the optimal (maximum benefit and minimal risk of side effects) antenatal corticosteroid dosing strategy remains unclear."( Betamethasone phosphate reduces the efficacy of antenatal steroid therapy and is associated with lower birthweights when administered to pregnant sheep in combination with betamethasone acetate.
Carter, S; Fee, EL; Furfaro, L; Jobe, AH; Kemp, MW; Newnham, JP; Saito, M; Schmidt, AF; Takahashi, T; Takahashi, Y; Usuda, H; Yaegashi, N, 2022
)
0.92
"Using an established sheep model of prematurity and postnatal ventilation of the preterm lamb, we aimed to compare the pharmacodynamic effects of low-dosage treatment with betamethasone acetate only against a standard dosage of betamethasone phosphate and betamethasone acetate as recommended by the American College of Obstetricians and Gynecologists for women at risk of imminent preterm delivery between 24 0/7 and 35 6/7 weeks' gestation."( Betamethasone phosphate reduces the efficacy of antenatal steroid therapy and is associated with lower birthweights when administered to pregnant sheep in combination with betamethasone acetate.
Carter, S; Fee, EL; Furfaro, L; Jobe, AH; Kemp, MW; Newnham, JP; Saito, M; Schmidt, AF; Takahashi, T; Takahashi, Y; Usuda, H; Yaegashi, N, 2022
)
1.11
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (8)

ClassDescription
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
steroid ester
fluorinated steroidA steroid which is substituted with one or more fluorine atoms in any position.
17alpha-hydroxy steroidThe alpha-stereoisomer of 17-hydroxy steroid.
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
11beta-hydroxy steroidAny 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
3-oxo-Delta(1),Delta(4)-steroidA 3-oxo-Delta(1) steroid containing an additional double bond between positions 4 and 5.
tertiary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID91224Antiinflammatory activity measured by using McKenzie-Stoughton human vasoconstrictor assay1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Computer-aided studies of the structure-activity relationships between the structure of some steroids and their antiinflammatory activity.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID90104Potency relative to fluocinolone 16,17-acetonide in the human vasoconstictor test1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (11.11)18.7374
1990's0 (0.00)18.2507
2000's2 (11.11)29.6817
2010's9 (50.00)24.3611
2020's5 (27.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.58 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index82.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (22.22%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (5.56%)4.05%
Observational0 (0.00%)0.25%
Other13 (72.22%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study [NCT03707795]Early Phase 16 participants (Actual)Interventional2017-08-21Completed
Evaluation of Potential Benefits of Using Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy [NCT02652884]Phase 4110 participants (Anticipated)Interventional2016-01-31Recruiting
Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars) [NCT04593706]40 participants (Anticipated)Interventional2020-11-01Not yet recruiting
Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance [NCT05058209]Phase 420 participants (Actual)Interventional2020-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]